Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia?

Introduction: A sustained-release tablet composed of a combination of the dopamine and norepinephrine reuptake inhibitor bupropion (BUP) and the µ-opioid receptor antagonist naltrexone (NAT) is marketed under the brand name Contrave by Orexigen Therapeutics for appetite control. Minimal literature is available regarding the use of combination bupropion and naltrexone (BUPNAT) in individuals with schizophrenia.

Areas Covered: In this review, we propose a theoretical model where BUPNAT may have a therapeutic effect in the treatment of schizophrenia.